Farmacorecensioni
Gli inibitori della pompa protonica
FEDERICO MARCHETTI, TANIA GHERARDUZZI, EGIDIO BARBI, STEFANO MARTELOSSI1, ALESSANDRO VENTURA
Clinica Pediatrica, IRCCS “Burlo Garofolo”, Universitŕ di Trieste
1Servizio di Gastroenterologia Pediatrica
Ottobre 2002 - pagg. 521 -526
Parole chiave
Suggerite dall'AI
Classificazione MeSH
Bibliografia
1. AA.VV. Progetto ARNO. Osservatorio sulla
prescrizione farmaceutica pediatrica. Rapporto
2000. CINECA 2002.
2. Gruppo Collaborativo Ospedaliero off-label- Pediatria. Prescrizione off-label nei reparti di Pediatria generale in Italia. Giornale Italiano di Farmacia clinica 2001;15(1):4-10.
3. Pandolfini C, Impicciatore P, Provasi D, et al. Off-label of drugs in Italy: a prospective, observational and multicentre study. Acta Paediatrica 2002;91:339-47.
4. Katelaris PH. New drugs, old drugs: proton pump inhibitors. Med J Australia 1998;169: 208-11.
5. Israel DM, et al. Omeprazole and other proton pump inhibitors: pharmacology, efficacy, and safety, with special reference to use in children. J Ped Gastroenterol Nutr 1998; 27:568-79.
6. Langtry HD, et al. Lansoprazole: an update of its pharmacological properties and clinical efficacy in the management of acid-related disorders. Drugs 1997;54:473-500.
7. Mathenson AJ, Jarvis B. Lansoprazole: an update of its place in the management of acid-related disorders. Drugs 2001;61(12): 1801-33.
8. Proton pump inhibitors. In: Olin BR (ed). Drug Facts and Comparisons. St. Louis: Facts and Comparisons, Inc., 1999:305k-r.
9. Tran A, Rey E, Pons G, et al. Pharmacokinetic- pharmacodynamic study of oral lansoprazole in children. Clin Pharmacol Ther 2002;71(5):359-67.
10. Walters JK, et al. The use of omeprazole in the pediatric population. Ann Pharmacother 1998;32:478-81.
11. Anonimo. Il testo delle nuove note. BIF 2000; 5-6:17.
12. Anonimo. Alcuni quesiti sulle note 1 e 48. BIF 2001; 4-5:160-3.
13. Cucchiara S, et al. Omeprazole and high dose ranitidine in the treatment of refractory reflux oesophagitis. Arch Dis Child 1993; 69:655-9.
14. Gunasekaran TS, et al. Efficacy and safety of omeprazole for severe gastroesophageal reflux in children. J Pediatr 1993;123: 148-54.
15. Karjoo M, et al. Omeprazole treatment of children with peptic esophagitis refractory to ranitidine therapy. Arch Pediatr Adolesc Med 1995;149:267-71.
16. Kato S, et al. Effect on omeprazole in the treatment of refractory acid-related diseases in childhood: endoscopic healing and twentyfour- hour intragastric acidity. J Pediatr 1996; 128:415-21.
17. De Giacomo C, et al. Omeprazole for severe reflux esophagitis in children. J Pediatr Gastroenterol Nutr 1997;24:528-32.
18. Hassall E, Israel D, Shepherd R, et al. Omeprazole for treatment of chronic erosive esophagitis in children: a multicenter study of efficacy, safety, tolerability and dose requirements. J Pediatr 2000;137:800-7.
19. Alliet P, et al. Omeprazole in infants with cimetidine-resistant peptic esophagitis. J Pediatr 1998;132:352-4.
20. Bohmer CJ, et al. Omeprazole: therapy of choice in intellectually disabled children. Arch Pediatr Adolesc Med 1998;152:1113-8.
21. Varughese LA, Mazur LJ. Is omeprazole helpful in the management of children with reflux oesophagitis? Arch Dis Child 2002;87: 78-80.
22. Kumar Y, Sarvananthan R. Gastro-oesophageal reflux in children. Clinical evidence. BMJ Publ Group 2002.
23. Katzka D. Gastro-esophageal reflux disease. In: Godlee F, 3 eds. Clinical Evidence London: BMJ Publ Group 2000:225-35.
24. Van Pinxeteren B, Numans ME, Bonis PA, Lau J. Short term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux diseaselike symptoms and endoscopy negative reflux disease. The Cochrane Library, Issue 3, 2002. Oxford: Update Software Ltd.
25. Labenz J, et al. Curing Helicobacter pylori infection in patients with duodenal ulcer may provoke reflux esophagitis. Gastroenterology 1997;112:1442-7.
26. Manes G, Mosca S, De Nucci C, et al. High prevalence of reflux symptoms in duodenal ulcer patients who develop gastro-oesophageal reflux disease after curing Helicobacter pylori infection. Dig Liver Dis 2001;33(8): 665-70.
27. Schwizer W, Thumshirn M, Dent J, et al. Helicobacter pylori and symptomatic relapse of gastro-oesophageal reflux disease: a randomised controlled trial. Lancet 2001;357: 1738-42.
28. Harris A, Misiewicz JJ. Management of Helicobacter pylori infection. BMJ 2001;323: 1047-50.
29. Chong SK. Gastrointestinal problems in the handicapped child. Curr Opin Pediatr 2001;13(5):441-6.
30. Dohil R, et al. Effective 2-wk therapy for Helicobacter pylori disease in children. Am J Gastroenterol 1997;92:244-7.
31. Kato S, et al. Omeprazole-based dual and triple regimens for Helicobacter pylori eradication in children. Pediatrics 1997;100: e3.
32. Moshkowitz M, et al. One-week triple therapy with omeprazole, clarithromycin, and nitroimidazole for Helicobacter pylori infection in children and adolescents. Pediatrics 1998; 102:e14.
33. Casswall TH, et al. One-week treatment with omeprazole, clarithromycin, and metronidazole in children with Helicobacter pylori infection. J Pediatr Gastroenterol Nutr 1998; 27:415-8.
34. Kato S, et al. Safety and efficacy of oneweek triple therapy for eradicating Helicobacter pylori in children. Helicobacter 1998; 3:278-82.
35. Gottrand F, Kalach N, Spyckerelle C, et al. Omeprazole combined with amoxicillin and clarithromycin in the eradication of Helicobacter pylori in children with gastritis: a prospective randomised double-blind trial. J Pediatr 2001;139:664-8.
36. Jones NL, Sherman PM. Approaching Helicobacter pylori infection in children: level I evidence at last and word of caution. J Pediatr 2001;139: 622-3.
37. Gold BD, Abbott M, Colletti R, et al. Evidence- based guidelines for an approach to the diagnosis and treatment of Helicobacter pylori infection in children: recommendations for diagnosis and treatment. J Pediatr Gastroenterol Nutr 2000;31:490-7.
38. Drumm B, Koletzeko S, Oderda G. Helicobacter pylori infection in children: a consensus steatment. J Pediatr Gastroenterol Nutr 2000;30:207-13.
39. Koch M, et al. Prevention of non steroidal anti-inflammatory drugs-induced gastrointestinal mucosal injury. A meta-analysis of randomised controlled clinical trial. Arch Internal Med 1996;156:2321-32.
40. Yeomans ND, et al. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal anti-inflammatory drugs. N Engl J Med 1998;338:719-26.
41. Hawkey CJ, et al. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal anti-inflammatory drugs. N Engl J Med 1998;338:727-34.
42. Miselli M. Gastroprotezione e corticosteroidi. Informazione sui farmaci 2001;2-3:54- 5.
43. Weil J, et al. Peptic ulcer bleeding: accessory risk factors and interactions with non-steroidal anti-inflammatory drugs. Gut 2000;46: 27-31.
44. De Giacomo C, et al. Omeprazole treatment of severe peptic disease associated with antral G cell hyperfunction and hyperpepsinogenemia I in an infant. J Pediatr 1990;117: 989-93.
45. Kaufman SS, Lyden ER, Brown CR, et al. Omeprazole therapy in pediatric patients after liver and intestinal transplantation. J Pediatr Gastroenterol Nutr 2002;34:194-8.
46. Francisco MP, Wagner MH, Sherman JM, et al. Ranitidine and omeprazole as adjuvant therapy to pancrelipase to improve fat absorption in patients with cystic fibrosis. J Pediatr Gastroenterol Nutr 2002;35(1):79-83.
47. Freston JW, et al. Safety profile of lansoprazole: the US clinical trial experience. Drug Safety 1999;20:195-205.
48. Romero-Gomez M, et al. Acute hepatitis related to omeprazole. Am J Gastroenterol 1999;94 (4):1119-20.
49. Pashankar DS, Israel DM, Jevon GP, Buchan AM. Effect of long-term omeprazole treatment on antral G and D cells in children. J Pediatr Gastroenterol Nutr 2001;33(5):537- 42.
50. Phillips J, et al. A prospective study of simplified omeprazole suspension for the prophylaxis of stress-related mucosal damage. Crit Care Med 1996;24:1793-800.
51. Quercia RA, et al. Stability of omeprazole in an extemporaneously prepared oral liquid. Am J Health-Syst Pharm 1997;54:1833-6.
2000. CINECA 2002.
2. Gruppo Collaborativo Ospedaliero off-label- Pediatria. Prescrizione off-label nei reparti di Pediatria generale in Italia. Giornale Italiano di Farmacia clinica 2001;15(1):4-10.
3. Pandolfini C, Impicciatore P, Provasi D, et al. Off-label of drugs in Italy: a prospective, observational and multicentre study. Acta Paediatrica 2002;91:339-47.
4. Katelaris PH. New drugs, old drugs: proton pump inhibitors. Med J Australia 1998;169: 208-11.
5. Israel DM, et al. Omeprazole and other proton pump inhibitors: pharmacology, efficacy, and safety, with special reference to use in children. J Ped Gastroenterol Nutr 1998; 27:568-79.
6. Langtry HD, et al. Lansoprazole: an update of its pharmacological properties and clinical efficacy in the management of acid-related disorders. Drugs 1997;54:473-500.
7. Mathenson AJ, Jarvis B. Lansoprazole: an update of its place in the management of acid-related disorders. Drugs 2001;61(12): 1801-33.
8. Proton pump inhibitors. In: Olin BR (ed). Drug Facts and Comparisons. St. Louis: Facts and Comparisons, Inc., 1999:305k-r.
9. Tran A, Rey E, Pons G, et al. Pharmacokinetic- pharmacodynamic study of oral lansoprazole in children. Clin Pharmacol Ther 2002;71(5):359-67.
10. Walters JK, et al. The use of omeprazole in the pediatric population. Ann Pharmacother 1998;32:478-81.
11. Anonimo. Il testo delle nuove note. BIF 2000; 5-6:17.
12. Anonimo. Alcuni quesiti sulle note 1 e 48. BIF 2001; 4-5:160-3.
13. Cucchiara S, et al. Omeprazole and high dose ranitidine in the treatment of refractory reflux oesophagitis. Arch Dis Child 1993; 69:655-9.
14. Gunasekaran TS, et al. Efficacy and safety of omeprazole for severe gastroesophageal reflux in children. J Pediatr 1993;123: 148-54.
15. Karjoo M, et al. Omeprazole treatment of children with peptic esophagitis refractory to ranitidine therapy. Arch Pediatr Adolesc Med 1995;149:267-71.
16. Kato S, et al. Effect on omeprazole in the treatment of refractory acid-related diseases in childhood: endoscopic healing and twentyfour- hour intragastric acidity. J Pediatr 1996; 128:415-21.
17. De Giacomo C, et al. Omeprazole for severe reflux esophagitis in children. J Pediatr Gastroenterol Nutr 1997;24:528-32.
18. Hassall E, Israel D, Shepherd R, et al. Omeprazole for treatment of chronic erosive esophagitis in children: a multicenter study of efficacy, safety, tolerability and dose requirements. J Pediatr 2000;137:800-7.
19. Alliet P, et al. Omeprazole in infants with cimetidine-resistant peptic esophagitis. J Pediatr 1998;132:352-4.
20. Bohmer CJ, et al. Omeprazole: therapy of choice in intellectually disabled children. Arch Pediatr Adolesc Med 1998;152:1113-8.
21. Varughese LA, Mazur LJ. Is omeprazole helpful in the management of children with reflux oesophagitis? Arch Dis Child 2002;87: 78-80.
22. Kumar Y, Sarvananthan R. Gastro-oesophageal reflux in children. Clinical evidence. BMJ Publ Group 2002.
23. Katzka D. Gastro-esophageal reflux disease. In: Godlee F, 3 eds. Clinical Evidence London: BMJ Publ Group 2000:225-35.
24. Van Pinxeteren B, Numans ME, Bonis PA, Lau J. Short term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux diseaselike symptoms and endoscopy negative reflux disease. The Cochrane Library, Issue 3, 2002. Oxford: Update Software Ltd.
25. Labenz J, et al. Curing Helicobacter pylori infection in patients with duodenal ulcer may provoke reflux esophagitis. Gastroenterology 1997;112:1442-7.
26. Manes G, Mosca S, De Nucci C, et al. High prevalence of reflux symptoms in duodenal ulcer patients who develop gastro-oesophageal reflux disease after curing Helicobacter pylori infection. Dig Liver Dis 2001;33(8): 665-70.
27. Schwizer W, Thumshirn M, Dent J, et al. Helicobacter pylori and symptomatic relapse of gastro-oesophageal reflux disease: a randomised controlled trial. Lancet 2001;357: 1738-42.
28. Harris A, Misiewicz JJ. Management of Helicobacter pylori infection. BMJ 2001;323: 1047-50.
29. Chong SK. Gastrointestinal problems in the handicapped child. Curr Opin Pediatr 2001;13(5):441-6.
30. Dohil R, et al. Effective 2-wk therapy for Helicobacter pylori disease in children. Am J Gastroenterol 1997;92:244-7.
31. Kato S, et al. Omeprazole-based dual and triple regimens for Helicobacter pylori eradication in children. Pediatrics 1997;100: e3.
32. Moshkowitz M, et al. One-week triple therapy with omeprazole, clarithromycin, and nitroimidazole for Helicobacter pylori infection in children and adolescents. Pediatrics 1998; 102:e14.
33. Casswall TH, et al. One-week treatment with omeprazole, clarithromycin, and metronidazole in children with Helicobacter pylori infection. J Pediatr Gastroenterol Nutr 1998; 27:415-8.
34. Kato S, et al. Safety and efficacy of oneweek triple therapy for eradicating Helicobacter pylori in children. Helicobacter 1998; 3:278-82.
35. Gottrand F, Kalach N, Spyckerelle C, et al. Omeprazole combined with amoxicillin and clarithromycin in the eradication of Helicobacter pylori in children with gastritis: a prospective randomised double-blind trial. J Pediatr 2001;139:664-8.
36. Jones NL, Sherman PM. Approaching Helicobacter pylori infection in children: level I evidence at last and word of caution. J Pediatr 2001;139: 622-3.
37. Gold BD, Abbott M, Colletti R, et al. Evidence- based guidelines for an approach to the diagnosis and treatment of Helicobacter pylori infection in children: recommendations for diagnosis and treatment. J Pediatr Gastroenterol Nutr 2000;31:490-7.
38. Drumm B, Koletzeko S, Oderda G. Helicobacter pylori infection in children: a consensus steatment. J Pediatr Gastroenterol Nutr 2000;30:207-13.
39. Koch M, et al. Prevention of non steroidal anti-inflammatory drugs-induced gastrointestinal mucosal injury. A meta-analysis of randomised controlled clinical trial. Arch Internal Med 1996;156:2321-32.
40. Yeomans ND, et al. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal anti-inflammatory drugs. N Engl J Med 1998;338:719-26.
41. Hawkey CJ, et al. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal anti-inflammatory drugs. N Engl J Med 1998;338:727-34.
42. Miselli M. Gastroprotezione e corticosteroidi. Informazione sui farmaci 2001;2-3:54- 5.
43. Weil J, et al. Peptic ulcer bleeding: accessory risk factors and interactions with non-steroidal anti-inflammatory drugs. Gut 2000;46: 27-31.
44. De Giacomo C, et al. Omeprazole treatment of severe peptic disease associated with antral G cell hyperfunction and hyperpepsinogenemia I in an infant. J Pediatr 1990;117: 989-93.
45. Kaufman SS, Lyden ER, Brown CR, et al. Omeprazole therapy in pediatric patients after liver and intestinal transplantation. J Pediatr Gastroenterol Nutr 2002;34:194-8.
46. Francisco MP, Wagner MH, Sherman JM, et al. Ranitidine and omeprazole as adjuvant therapy to pancrelipase to improve fat absorption in patients with cystic fibrosis. J Pediatr Gastroenterol Nutr 2002;35(1):79-83.
47. Freston JW, et al. Safety profile of lansoprazole: the US clinical trial experience. Drug Safety 1999;20:195-205.
48. Romero-Gomez M, et al. Acute hepatitis related to omeprazole. Am J Gastroenterol 1999;94 (4):1119-20.
49. Pashankar DS, Israel DM, Jevon GP, Buchan AM. Effect of long-term omeprazole treatment on antral G and D cells in children. J Pediatr Gastroenterol Nutr 2001;33(5):537- 42.
50. Phillips J, et al. A prospective study of simplified omeprazole suspension for the prophylaxis of stress-related mucosal damage. Crit Care Med 1996;24:1793-800.
51. Quercia RA, et al. Stability of omeprazole in an extemporaneously prepared oral liquid. Am J Health-Syst Pharm 1997;54:1833-6.